RT Journal Article
SR Electronic
T1 Practical Considerations for Implementation of <sup>177</sup>Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 195
OP 202
DO 10.2967/jnmt.122.263813
VO 50
IS 3
A1 Soulek, Diane K.
A1 Martin, Molly E.
A1 Mastascusa, Nic J.
A1 Graves, Stephen A.
YR 2022
UL http://tech.snmjournals.org/content/50/3/195.abstract
AB The 2018 Food and Drug Administration approval of 177Lu-DOTATATE for the treatment of somatostatin receptor–positive neuroendocrine tumors (NETs) represents a paradigm-shifting approach to cancer treatments around the globe. Gastroenteropancreatic NETs overexpress the somatostatin subtype receptor 2, which is now exploited for receptor-based imaging and therapy, thus generating significant progress in the diagnosis and treatment of this orphan disease. The recent Food and Drug Administration approval of receptor-based PET radiopharmaceuticals and a new peptide receptor radiopharmaceutical therapy, 177Lu-DOTATATE, has dramatically impacted NET patient management. The focus of this paper is to review clinical considerations associated with implementing a 177Lu-DOTATATE program. We review receptor-based NET radiopharmaceuticals; 177Lu-DOTATATE patient selection criteria; administration methods; clinical, regulatory, and radiation safety considerations; technical factors; tissue dosimetry; and reimbursement guidelines.